Cross-reactivity: what the evidence shows.

Modern published evidence indicates that cross-reactivity between sulfa antibiotics and non-antibiotic sulfonamides — drugs like furosemide, HCTZ, celecoxib, the sulfonylureas, and acetazolamide — is low. The historical assumption that all sulfonamides cross-react is no longer well supported. The decision in any given patient still belongs to the prescribing clinician.

Educational reference — not medical advice. This page describes what is generally known about a drug family. It cannot account for your history, your other medicines, or your circumstances. Decisions about your own treatment belong with your doctor or pharmacist.

The summary, in one sentence. Sharing the –SO₂NH₂ group does not, on its own, mean two drugs share immunogenic potential — and most allergic reactivity to sulfa antibiotics is driven by the arylamine at the N4 position, which the non-antibiotic sulfonamides lack.

Old view: "Sulfa allergic" patients should avoid all sulfonamides.
Modern view: Cross-reactivity between sulfa antibiotics and non-antibiotic sulfonamides is low.
Mechanism: The N4 arylamine drives most antibiotic-type immune reactivity; non-antibiotic sulfonamides lack it.
Clinical caveat: Patients with one drug allergy have a higher background risk of others, regardless of structural similarity.

The structural reason

Drugs labelled "sulfonamides" share the chemical group –SO₂NH₂. Beyond that, they differ. Sulfa antibiotics carry an arylamine at the N4 position — an amine group attached to a benzene ring at a specific location. The arylamine is what allows the drug to mimic PABA and act as an antibacterial. It is also responsible for most of the immune reactivity, through reactive metabolites that bind to host proteins.

Most non-antibiotic sulfonamides do not have this arylamine. Their backbones are different. Their immunogenic pathway, where they have one, is also different. The shared –SO₂NH₂ group is, by itself, not what drives the allergic reactivity. The chemistry page covers this; antibiotic vs non-antibiotic sulfonamides goes deeper.

What the published evidence shows

The reference study is Strom and colleagues, published in the New England Journal of Medicine in 2003 under the title "Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics." It followed patients in a large UK general practice database. Among 969 people who had previously reacted to a sulfa antibiotic, 9.9% reacted when later given a non-antibiotic sulfonamide. Among 19,257 people with no such history, 1.6% did — an adjusted odds ratio of 2.8.

This study is very widely misreported, including by sites that should know better. Its title says "absence of cross-reactivity," and it is routinely summarised as showing no increased risk. It showed nothing of the sort: the risk was roughly tripled, and that difference was statistically solid. What the study established is not that the risk vanishes but that the sulfonamide group is not what causes it.

The evidence for that conclusion is in the comparison the authors built in. The same sulfa-allergic patients were more likely to react to penicillin — adjusted odds ratio 3.9 — than to a non-antibiotic sulfonamide, and penicillin shares no relevant chemistry with sulfonamides whatsoever. Set side by side, a sulfa-allergic patient was actually somewhat less likely to react to a sulfonamide non-antibiotic than to a penicillin. If the shared –SO₂NH₂ group were driving the reactions, that ordering would be reversed.

The accepted reading, then, is that people who have reacted to one drug are simply more likely to react to drugs in general — sometimes called multiple drug intolerance syndrome, or just a higher background allergic predisposition. The elevated rate is real and worth knowing about. It is not evidence of a shared allergen. Subsequent reviews and pharmacovigilance work have supported this picture, and the 2022 AAAAI/ACAAI drug allergy practice parameter concludes there is "minimal concern for cross-reactivity" between the two groups.

The study's limits are worth naming too. It relied on diagnostic codes for "allergic reaction" rather than confirmed, challenge-proven allergy, and it did not characterise what kind of reaction each patient had. It is good evidence about populations and weak evidence about any individual.

None of this evidence implies that cross-reactivity is zero. There are individual case reports of patients reacting to multiple sulfonamides. The signal at the population level, however, does not support a class-wide avoidance rule.

Practical implications

For a patient with a documented allergy to a sulfa antibiotic, the modern, evidence-based approach to non-antibiotic sulfonamides is roughly:

For mild past reactions (typical maculopapular rash, no systemic features, no severe cutaneous reaction), most clinicians are comfortable using non-antibiotic sulfonamides such as furosemide, HCTZ, celecoxib, sulfonylureas, and acetazolamide. Some monitor more closely on first dose; some prescribe routinely.

For severe past reactions — Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, or anaphylaxis — most clinicians take a more cautious view. Even though the structural argument suggests low cross-reactivity, the consequences of a severe reaction recurring are large. Decisions in this group are individualised and often involve specialist input. More on severity.

For sulfasalazine, the picture is different. Sulfasalazine is metabolised to sulfapyridine, which carries an antibiotic-type arylamine. Patients with sulfa antibiotic allergy may react to sulfasalazine, and the same caution that applies to sulfa antibiotics broadly applies here.

For dapsone — technically a sulfone, not a sulfonamide — the cross-reactivity question is separate. Dapsone has its own allergy profile and its own concerns (notably G6PD deficiency). It is not interchangeable with sulfa antibiotics.

What labels say, and what they mean

Many drug labels for non-antibiotic sulfonamides — particularly older labels — carry historical warnings against use in "sulfa-allergic" patients. These warnings predate the modern evidence and reflect a more conservative regulatory posture. They have not been universally updated to reflect contemporary studies. A clinician reading the label is aware of both the wording and the underlying data.

Cross-reactivity is a population statistic. It tells you the average risk in a group of patients, not the certainty in one patient. If your past reaction was severe, structural arguments do not override clinical caution. The decision to use a related drug rests with your prescriber.

References

Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628-35. pubmed.ncbi.nlm.nih.gov
Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022;150(6):1333-93. www.jacionline.org
Can my patient with a "sulfa allergy" receive celecoxib or other nonantimicrobial sulfonamides? Cleve Clin J Med. 2025;92(3):147. www.ccjm.org